Newsroom
  • Press Releases
  • Presentations
Investors
  • Overview
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • Notice to Stockholders
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
Clinical Trial Enrollment
  • Triple-Negative Breast Cancer
  • COVID-19 Mild to Moderate
  • COVID-19 Severe or Critical
Contact

CytoDyn Inc.

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
    • Overview
    • HIV
    • Cancer
    • GVHD
    • COVID-19
  • Expanded Access
  • Our Team
    • Management Team
    • Board of Directors
  • Careers
    • Now Hiring
  • Scientific Board of Advisors
  • Newsroom
  • Investors
  • Clinical Trial Enrollment
  • Contact
Latest News

FOR THE LATEST DEVELOPING NEWS Click Here

Hospitals Enrolling COVID-19 Severe-to-Critical

Investment Community Webcast on Monday, March 8

Antibody-based strategies in HIV therapy

Dr. Seethamraju’s Presentation at Special isirv-AVG Virtual Conference

Manuscript Accepted by Infectious Diseases Society of America

Into the Looking Glass: Post-Viral Syndrome Post COVID-19

EUA for COVID-19 Vaccines and Treatments in the Philippines

Leronlimab’s Mechanism of Action in COVID-19 Published

Leronlimab role in COVID-19

Experimental Drugs Aim to Treat Long-Haul Covid Patients

Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity

Leronlimab and Long-Haulers

Latest Publication Leronlimab Blocks Breast Cancer

CytoDyn Q&A with CEO Nader Pourhassan - January 26

Press Releases

Newsroom

Newsroom

  • Press Releases
  • Presentations

CytoDyn’s Two-Year Update on Its PRO 140 Monotherapy Study in HIV Accepted at CROI 2017

Nov 16, 2016 6:30am EST

CytoDyn Announces Webcast of Investment Community Presentation on November 11

Nov 09, 2016 6:30am EST

CytoDyn Files Protocol for Extended Access to PRO 140 for Patients Who Reach the End of PRO 140 Pivotal Phase 3 Trial

Oct 24, 2016 6:30am EDT

CytoDyn Announces Favorable Protocol Modifications for Pivotal Phase 3 Combination Trial With PRO 140 After Positive FDA Meeting

Oct 06, 2016 6:30am EDT

CytoDyn Announces $10.0 Million Registered Direct Offering

Sep 12, 2016 9:11am EDT

CytoDyn to Present at Rodman & Renshaw Global Investment Conference on September 12

Sep 07, 2016 5:25pm EDT

Patients Approach Two Years of Complete HIV Viral Load Suppression in Phase 2b PRO 140 Monotherapy Extension Study

Aug 23, 2016 6:30am EDT

CytoDyn Announces Investment Community Conference Call for August 19, 2016

Aug 17, 2016 4:09pm EDT

First Patient Enrolled Under Newly Modified Protocol in CytoDyn’s Phase 3 PRO 140 Combination Study in HIV

Jul 26, 2016 6:30am EDT

CytoDyn Submits Orphan Drug Application to FDA for Pretreatment With PRO 140 of Treatment-Naïve HIV Patients

Jul 21, 2016 6:30am EDT
RSS
  • Prev
    • 1...
    • 21
    • 22
    • 23
    • 24
    • 25
    • 26
    • 27
    • 28
    • 29
    • 30
    • ...33
    Next
    © 2021 CytoDyn Inc. All Rights Reserved.
    • Twitter
    • Facebookj
    Privacy Policy Disclaimer Sitemap